Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

Shelley Wood

October 08, 2021

News Features

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

Caitlin E. Cox

April 23, 2020

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Shelley Wood

December 30, 2016

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Features

Thoughtful Insights at TCT: Dealing With Complex CAD Cases

Todd Neale

October 17, 2014

News Features

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

Todd Neale

October 10, 2014

News Features

FDA Label Change Fails to Stem Uncertainty Over PPI Use with Clopidogrel

Caitlin E. Cox

May 07, 2012

Advertisement

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Top News in Prevention: 2018

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Thoughtful Insights at TCT: Dealing With Complex CAD Cases

Thoughtful Insights at TCT: Uncertainty Surrounds Antithrombotic Therapy in PCI Patients Who Require Anticoagulation

FDA Label Change Fails to Stem Uncertainty Over PPI Use with Clopidogrel

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content